2 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Withdrawn 2 |
Follow Hyperglycemia: new trials by email Literature Review of Hyperglycemia trials Research Report on Hyperglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded) - Diabetes Mellitus, Type 2, Pre-diabetic | Phase 3 | Withdrawn | University of Pennsylvania | 2018-06-01 | 2026-09-21 | |
| Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia insulin glargine recombinant, therapeutic insulin - Hyperglycemia, Leukemia | Phase 3 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2009-05-01 | 2013-08-30 |
Congenital Abnormalities (1) · Diabetes Mellitus, Type 2 (1) · Glucose Intolerance (1) · Hypertension (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1)
Insulin (1) · Insulin Glargine (1) · Valsartan (1) · sacubitril (1) · sacubitril and valsartan sodium hydrate drug combination (1)
University of Medicine and Dentistry of New Jersey (1) · University of Pennsylvania (1)
United States (2)
Jessica R Wilson, MD, MSCI (1) · Mecide Gharibo, MD (1)
P30CA072720 (1)